Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 27, 2009

CLC bio to Provide Next-Generation Sequencing Solutions in Japan Through Filgen

  • CLC bio is expanding the distribution of its next-generation sequencing solutions into the Japanese market through a deal with Filgen. “In 2009, we have experienced a considerable increase of interest in our solutions from Japan,” according to director of partner sales at CLC bio, Michael Heltzen.

    “This is logically linked with the significant increase of next-generation sequencing instruments being installed, which in turn requires analysis capacity of the huge amounts of data, an area where we excel. We regard the Japanese life science sector as one of the premier markets in Asia and are happy to announce this setup, so we can support our current and upcoming customers in Japan in the best possible way.”

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »